Bridge Biotherapeutics Presented Preclinical and Phase I Study Results for BBT401 at the Crohn's & Colitis Congress

SEONGNAM South Korea Feb. 11 2019 PRNewswire Bridge Biotherapeutics Inc. a clinical stage biotech company headquartered in Seongnam South Korea announced that the company presented the preclinical and the Phase I study results for BBT401 a drug candidate ...